Healthcare / BiotechnologyLSE
$15.50
+0.50 (+3.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-15.5M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$81M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-277.7%
↓Gross Margin
64.5%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-7.3%
FCF CAGR
—
FCF margin
-756.5%
FCF / Net income
0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.0M · net income $-19.1M · FCF $-15.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.0M | $2.0M | $1.2M | $638000.00 | $2.6M |
| Net Income | $-19.1M | $-19.1M | $-14.4M | $-19.4M | $-50.1M |
| EBITDA | $-18.5M | $-18.5M | $-13.8M | $-18.8M | $-48.4M |
| EPS | -0.07 | -0.07 | -0.07 | -0.10 | -0.63 |
| Gross Margin | 64.5% | 64.5% | 58.4% | 45.0% | 48.8% |
| Operating Margin | -949.0% | -949.0% | -1230.7% | -2940.9% | -682.0% |
| Net Margin | -932.1% | -932.1% | -1198.0% | -3036.4% | -1949.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.26 | 0.08 | 0.02 |
| Current Ratio | 0.96 | 0.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.5M | $-15.5M | $-13.8M | $-16.7M | $-12.6M |
| Returns | |||||
| ROE | -277.7% | -277.7% | -691.2% | -166.4% | -168.9% |
| Valuation | |||||
| P/B | 618.92 | 618.92 | 827.21 | 342.58 | 149.03 |
| Growth & Yield | |||||
| Revenue Growth | 70.3% | 70.3% | 88.6% | -75.2% | — |
| EPS Growth | 0.0% | 0.0% | 30.0% | 84.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+82.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.07 → -0.07
Residual
+82.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.